MYGN, the Next AMGN

[NY4Ever]

Drug Development Pipeline--- MYGN
Our drug development efforts target cancer, Alzheimer's disease, thrombosis, HIV/AIDS and other viral diseases. In addition, we have a number of other lead optimization programs within these disease areas.

Molecule Therapeutic Area Status
Flurizan™ Alzheimer's Disease Phase 3
MPC-7869 Prostate Cancer Phase 2b
MPC-6827 Brain Cancer Phase 1
MPC-6827 Solid Tumors Phase 1
MPC-2130 Blood Cancers Phase 1
MPC-0920 Thrombosis Preclinical
MPI-49839 HIV/AIDS Preclinical
MPC-4505 Cancer Preclinical
MPI-42511 Cancer Preclinical
MPI-442691 Alzheimer's Disease Preclinical

[NY4Ever]

Mygn

FMR reported a 10.18% stake in biopharmaceutical company Myriad Genetics (MYGN

The Next AMGN

[Karel]

Hi NY4Ever,

please keep your MYGN posts in one thread; it will be easier for others to follow developments.

Regards,

Karel

[NY4Ever]

Fantastic pipeline ready to explode. Very small float.

[NY4Ever]

Just a friendly reminder.

[NY4Ever]

Breaking out of its up channel.

[skiracer]

Breaking out of its up channel.

I'm in from $22.00 range. Was waiting for this. Nice move today. Also holding ELN from $13.85 and gold ETF GLD from $465 area. MYGN terrible fundamentals but alot in the pipeline.

[NY4Ever]

09-Feb-2006
1:00 PM ET Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Event type: Corporate Presentation
Presenter: Peter D. Meldrum, President & CEO MYGN
Location: Grand Hyatt, New York, NY

[NY4Ever]

At J. P. Morgan conference, CEO Peter Meldrum was very excited about 6827 drug for metastatic brain cancer saying the people at M. D. Anderson feel the same way.

[NY4Ever]

My pick of the week and up almost 10% today on big volume and a good earnings report. More good news coming Thursday. 2.5 million shares short.

[NY4Ever]

My pick of the week and up almost 10% today on big volume and a good earnings report. More good news coming Thursday. 2.5 million shares short.>>

UPGRADE: JMP Securities from overweight to strong buy. Target 29.

[NY4Ever]

Up 17% this week thus far.

[NY4Ever]

MYGN has 39 million shares outstanding, 235 million in cash and marketable securities, 2.5 million shares short, a fast growing and very profitable PM business and a pipeline of which 3 drugs could be blockbusters of one billion plus. Cancer drug 6827 has a good chance of getting fast track status. Do your own research.

[Lyehopper]

Up 17% this week thus far.

Great pick dude!

[Jim Smith]

gotta give you props on this, you sniffed this one out....gap above resistance.....